Search:

DEVA

A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer.

Disease site: Breast cancer

Treatment Modality: Chemotherapy

Status: Closed

Trial details

The DEVA trial was run by the International Collaborative Cancer Group (ICCG) at Imperial College London in collaboration with ICR-CTSU.

Chief Investigator: Professor R. C. Coombes, Imperial College London

ICR-CTSU Scientific Lead: Professor Judith Bliss

ISRCTN: 89772270

Sponsor: International Collaborative Cancer Group (ICCG)

Funding: Pfizer, Sanofi-Aventis

Further information

Further information on the DEVA trial may be found on the following sites:

Patient friendly summary of the DEVA trial results at CancerHelp UK

Publications and presentations

Coombes RC, Bliss JM, Espie M, et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J. Clin. Oncol. 2011;29(24):3247-54

Coombes RC, Bliss JM, Espie M, et al. DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients. J. Clin. Oncol. 2010;28(15_suppl):536

Red, yellow and blue microscope image of immunofluorescence staining showing extension of prostatic adenocarcinoma into the bladder wall

New drug hope for prostate cancer patients

10/01/25

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.

ICR welcomes NICE recommendation of olaparib for advanced breast cancer

09/01/25

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.